Respiratory syncytial virus (RSV) is an RNA virus that infects human respiratory epithelial cells and causes annual outbreaks of respiratory tract disease among infants and young children as well as recurrent infections throughout life. Annual outbreaks of RSV disease are attributable to first-time infection in susceptible infants, to reinfection in children and adults with waning or incomplete immunity, and to infection by viral genotypes with sufficient antigenic variation to avoid innate and acquired immunity. In industrialized countries, few infectious diseases have a greater effect on the health of young children than does lower respiratory tract disease caused by RSV. By 2 years of age, almost all children will experience an RSV infection and approximately 50% will be infected twice. 
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intervention. 8 A number of economic analyses of palivizumab prophylaxis have been published. [9] [10] [11] [12] [13] [14] Results demonstrate that the increased cost associated with palivizumab prophylaxis far exceeds the cost savings from reduced hospitalizations. No effect on subsequent reactive airway disease or asthma rates has been demonstrated from palivizumab prophylaxis in a prospective, randomized trial. Even when a possible effect on quality of life is considered in the cost analysis, cost savings from a reduction in asthma cannot be demonstrated. 13 The increase in cost associated with palivizumab use is not offset by a reduction in mortality rates, because neither of the 2 clinical trials with palivizumab (and none of the 3 trials with RSV hyperimmune globulin) demonstrated a statistically significant reduction in mortality rates.
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In the IMpact-RSV trial, the number needed to treat with palivizumab to prevent one hospitalization among infants in the 32 to 35 weeks' gestational age group without chronic lung disease based on a 78% reduction (8.1% versus 1.8%, placebo versus active drug) in hospitalization was 15.9. 6,15 Thus, the cost of prophylaxis to prevent one RSV hospitalization in this gestational age cohort was approximately $95 000 ($6000 cost of prophylaxis per infant per season x 15.9 infants). 15 The cost saving per RSV hospitalization avoided typically is less than $10 000, meaning the net cost of preventing one RSV hospitalization was approximately $85 000. 15 This is a crude figure, because it does not include additional costs, such as administration fees or drug wastage. It also does not include additional potential savings such as a reduction in outpatient visits or avoidance of indirect costs associated with hospitalization.
Nonetheless, the overriding conclusion is that palivizumab prophylaxis results in a substantial increase in cost, a very small increase in quality adjusted life-years as a result of decreased hospitalizations, and no reduction in mortality. No national guidelines have been established to
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determine a value for prevention of one RSV hospitalization, but the cost of palivizumab prophylaxis is high relative to the benefit derived.
Given the large number of infants who require prophylaxis to prevent one hospitalization, it would be desirable to identify infants most likely to experience severe RSV disease. The ability to target prophylaxis at infants who are at greatest risk of intensive care admission or need for mechanical ventilation or prolonged hospitalization would represent optimal use of this intervention. Unfortunately, published studies do not enable identification of those infants at greatest risk of increased morbidity or mortality. Although numerous risk factors for hospitalization have been identified, such factors either are found inconsistently or have a minimal effect on the risk of hospitalization (less than two-to fourfold). [16] [17] [18] [19] [20] [21] [22] [23] Because of this uncertainty, other countries, including Canada, rarely recommend palivizumab prophylaxis for infants born in the 32 to 35 weeks' gestational age category.
In an effort to simplify the guidelines and to optimize prophylaxis for infants in the 32 weeks, 0 days' through 34 weeks, 6 days' gestational age cohort, the 2009 AAP recommendations have been broadened to include a larger number of infants during the period of greatest risk. The most consistently identified risk factor for RSV hospitalization among infants is chronologic age less than 90 days. [16] [17] [18] [19] [20] [21] [22] [23] Once a child exceeds 90 days of age, the risk of RSV hospitalization declines. Using the 2009 AAP recommendations, infants born 3 months before or during the RSV season require only 1 of 2 epidemiologic factors to qualify for prophylaxis:
1. presence of an older sibling or child younger than 5 years living in the same household; or 2. attendance at child care.
